Compare MVBF & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MVBF | SENS |
|---|---|---|
| Founded | 1997 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Industrial Machinery/Components |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 371.6M | 301.2M |
| IPO Year | 2004 | 2014 |
| Metric | MVBF | SENS |
|---|---|---|
| Price | $30.58 | $7.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $29.50 | $18.38 |
| AVG Volume (30 Days) | 32.9K | ★ 601.4K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | ★ 34.64 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | $3,400,000.00 | ★ $16,389,000.00 |
| Revenue This Year | $1.70 | $74.15 |
| Revenue Next Year | $13.59 | $58.60 |
| P/E Ratio | $22.91 | ★ N/A |
| Revenue Growth | ★ 51.92 | 19.85 |
| 52 Week Low | $22.85 | $0.41 |
| 52 Week High | $31.99 | $8.75 |
| Indicator | MVBF | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 60.19 | 76.46 |
| Support Level | $24.71 | $7.35 |
| Resistance Level | $31.99 | $8.49 |
| Average True Range (ATR) | 0.81 | 0.44 |
| MACD | -0.05 | 0.37 |
| Stochastic Oscillator | 65.44 | 78.38 |
MVB Financial Corp is a financial holding company. The company provides a wide range of business activities through the Bank, commercial and retail banking services, as well as Fintech banking. It has three reportable segments: CoRe Banking, Mortgage Banking, and Financial Holding Company. The majority of its revenue is generated from the CoRe Banking segment, which includes its Fintech division, represents banking products and services offered to customers by the Bank, loans and deposits accounts. Revenue from banking activities consists of interest earned on loans and investment securities and service charges on deposit accounts.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.